BrainsWay demonstrates a strong, defensible core business model centered on proprietary Deep TMS technology with FDA clearance and clinical validation. Its transition towards recurring revenue models and multi-year enterprise partnerships enhances growth sustainability and revenue predictability. T…
BrainsWay (BWAY) Q1 2025: Deep TMS System Shipments Surge 42%, Backlog Nears $60 Million
BrainsWay accelerated growth with a substantial increase in Deep Transcranial Magnetic Stimulation (Deep TMS) system placements and a nearly $60 million backlog, signaling strong demand and broadening enterprise adoption. The company’s focus on expanding recurring revenue streams and advancing clinical protocols underpins its leadership in noninvasive neurostimulation. Continued R&D and global expansion initiatives position BrainsWay for sustained growth amid evolving mental health treatment landscapes.
Summary
- Enterprise Partnership Expansion: Multi-year agreements deepen customer engagement beyond one-time sales.
- Clinical Leadership Reinforced: Growing adoption in OCD and anxious depression supports platform differentiation.
- Innovation Pipeline Advancing: Accelerated treatment protocols and new device development target broader indications.
Business Overview
BrainsWay is a global leader in noninvasive neurostimulation, specializing in Deep Transcranial Magnetic Stimulation (Deep TMS) technology for mental health disorders. The company generates revenue primarily through sales and placements of Deep TMS systems, along with associated recurring revenue models such as pay-per-use and leasing. Its major segments include system sales, clinical services, and ongoing research and development aimed at expanding approved treatment indications.
Performance Analysis
BrainsWay reported first quarter 2025 revenue of $11.5 million, marking a 27% year-over-year increase driven by a 42% surge in Deep TMS system shipments to 81 units. This shipment growth reflects both new customer acquisitions and expansion within existing accounts, with approximately 80% of sales attributed to greenfield opportunities. The company maintained a strong gross margin of 75%, consistent with the prior year, underscoring effective cost management despite global tariff uncertainties.
Operating profit rose sharply to $0.6 million, a 519% increase compared to the same period last year, supported by disciplined expense control amid revenue growth. Adjusted EBITDA improved 81% to $1.3 million, marking the seventh consecutive quarter of positive adjusted EBITDA. Net profit expanded nearly ninefold to $1.1 million, reflecting operational leverage and growing scale. The install base grew to 1,434 systems, up from 1,158 a year earlier, reinforcing BrainsWay’s market leadership position.
- Revenue Growth and Margin Stability: 27% revenue growth paired with steady 75% gross margin highlights scalable model.
- Backlog Visibility: Nearly $60 million in backlog provides strong forward revenue visibility.
- Recurring Revenue Expansion: Pay-per-use and leasing models contribute to predictable, sustainable cash flow.
Overall, BrainsWay’s financial performance indicates robust demand for its Deep TMS platform, driven by both clinical efficacy and expanding commercial reach, laying a solid foundation for future growth.
Executive Commentary
"We shipped a total of 81 Deep TMS systems, representing a 42% increase compared to the first quarter of 2024. We have signed the backlog and remaining performance obligation totaling nearly $60 million, providing clear visibility into future growth."
Hadar Levy, Chief Executive Officer
"Our team has done a tremendous job balancing our expense management while generating this high level of revenue growth. This has allowed us to consistently report strong gross margin of 75%, increased operating income and adjusted EBITDA margin, and generated positive cash flow from operations."
Ido Marom, Chief Financial Officer
Strategic Positioning
1. Enterprise Customer Engagement and Recurring Revenue Models
BrainsWay has shifted from a traditional one-time sales approach to cultivating deeper partnerships with large enterprise networks through multi-year agreements. This strategy includes enhanced customer service tailored to evolving account needs and the scaling of flexible pay-per-use and leasing models. These efforts aim to create a more predictable revenue stream and foster long-term customer loyalty, reducing dependency on upfront system sales.
2. Clinical Differentiation and Market Leadership
The company’s Deep TMS platform is distinguished by FDA-cleared indications for major depressive disorder (including anxious depression) and obsessive-compulsive disorder (OCD), with clinical data supporting efficacy. BrainsWay continues to gain market share as customers switch from competitor technologies, citing superior clinical outcomes and economic value. The growing installed base and coil shipments underscore increasing adoption across multiple indications.
3. Research and Development Pipeline Advancement
BrainsWay is progressing a randomized multicenter U.S. clinical trial evaluating an accelerated Deep TMS treatment protocol for major depressive disorder, with FDA clearance expected by year-end. The company is also preparing data submissions for PTSD and adolescent MDD indications and exploring combination protocols with psychedelic treatments. These R&D initiatives aim to broaden the platform’s therapeutic reach and improve treatment convenience, enhancing patient appeal.
4. Global Expansion and Market Penetration
Expanding beyond the U.S., BrainsWay is growing its presence in Canada, Asia, India, and Europe, leveraging regulatory approvals and reimbursement advancements, such as in Israel for PTSD. This geographic diversification supports revenue growth and access to larger patient populations, positioning the company to capitalize on rising global demand for noninvasive mental health treatments.
5. Innovation with Next-Generation Devices
The upcoming Deep TMS 360™ system targets shorter treatment times and potential efficacy improvements in areas like dementia and addiction. The device is expected to complement or replace existing systems depending on customer needs, creating new opportunities in underpenetrated segments such as addiction treatment. This product innovation aligns with BrainsWay’s strategy to sustain technological leadership.
Key Considerations
BrainsWay’s first quarter reflects strategic execution on multiple fronts, balancing growth, innovation, and operational discipline.
- Market Expansion vs. Competitive Conversion: Approximately 80% of new system sales are to new customers, indicating strong market growth rather than solely competitor displacement.
- Flexible Business Models: The pay-per-use model, especially in Israel, offers providers lower upfront costs and aligns revenue with procedure volumes, supporting adoption.
- Clinical Trial Milestones: Expected FDA clearances for accelerated protocols and new indications could materially expand market potential.
- Tariff and Geopolitical Monitoring: While management sees no material current impact, ongoing vigilance is essential given global trade uncertainties.
- Capital Allocation Focus: With $72 million in cash, management prioritizes growth investments and innovation over share repurchases at this time.
Risks
Potential risks include regulatory delays or setbacks in clinical trial outcomes, which could slow indication expansion. Geopolitical and tariff policy shifts remain uncertain and could affect supply chains or costs. Increased competition or slower-than-expected adoption in new markets also pose challenges to growth projections.
Forward Outlook
For the full year 2025, BrainsWay reiterated guidance for revenue between $49 million and $51 million, representing 20% to 24% growth over 2024. Operating profit is expected between 3% and 4% of revenue, with adjusted EBITDA margins of 11% to 12%. Management emphasized continued momentum driven by backlog visibility, clinical advancements, and international expansion as key factors supporting this outlook.
Takeaways
BrainsWay’s Q1 results highlight a company capitalizing on strong demand for its differentiated Deep TMS platform, supported by operational efficiency and strategic customer engagement.
- Growth Engine: The 42% increase in system shipments and nearly $60 million backlog demonstrate robust market traction and revenue visibility.
- Strategic Shift to Recurring Revenue: Expansion of pay-per-use and leasing models reflects a deliberate move toward more sustainable and predictable cash flows.
- Innovation and Clinical Expansion: Progress in accelerated protocols and new device development positions BrainsWay to extend its leadership in neurostimulation treatments.
Conclusion
BrainsWay’s first quarter 2025 performance reinforces its leadership in the noninvasive neurostimulation market through strong commercial execution, clinical innovation, and strategic expansion. The company’s balanced approach to growth and expense management, coupled with a promising R&D pipeline, supports confidence in achieving full-year targets and long-term value creation.
Industry Read-Through
BrainsWay’s results underscore the growing acceptance and clinical validation of noninvasive neurostimulation therapies as alternatives to pharmacological treatments for mental health disorders. The expansion of flexible revenue models and multi-indication pipelines reflects broader industry trends toward patient-centric, value-based care. Other neurotechnology companies may look to BrainsWay’s strategic emphasis on enterprise partnerships and recurring revenue as a blueprint for sustainable growth amid evolving healthcare reimbursement and regulatory landscapes.